Skip to content
My WebMD Sign In, Sign Up

Cancer Health Center

Font Size

Late Effects of Treatment for Childhood Cancer (PDQ®): Treatment - Health Professional Information [NCI] - Late Effects of the Reproductive System

continued...

The presence of apparently normal ovarian function at the completion of chemotherapy should not be interpreted as evidence that no ovarian injury has occurred. Premature menopause is well documented in childhood cancer survivors, especially in women treated with both an alkylating agent and abdominal irradiation.[45,46,47] A total of 126 childhood cancer survivors and 33 control siblings who participated in the CCSS developed premature menopause. Of these women, 61 survivors (48%) and 31 siblings (94%) had surgically-induced menopause (relative risk [RR] = 0.8; 95% confidence interval [CI] = 0.52–1.23). However, the cumulative incidence of nonsurgical premature menopause was substantially higher for survivors than for siblings (8% vs. 0.8%; RR = 13.21; 95% CI, 3.26–53.51; P < .001).[45]
cdr0000719145.jpg
Figure 6. Cumulative incidence curves of nonsurgical premature menopause in survivors (solid line) compared with siblings (broken line). Vertical bars indicate 95% confidence intervals. Sklar C A et al. JNCI J Natl Cancer Inst 2006;98:890-896. ©Sklar 2006. Published by Oxford University Press.

A multiple Poisson regression model showed that risk factors for nonsurgical premature menopause included attained age, exposure to increasing doses of radiation to the ovaries, increasing alkylating agent dose score, and a diagnosis of Hodgkin lymphoma. For survivors who were treated with alkylating agents plus abdominal-pelvic radiation, the cumulative incidence of nonsurgical premature menopause approached 30%.[45]

In Europe, survivors of Hodgkin lymphoma treated between the ages 15 years and 40 years and who were not receiving hormonal contraceptives were surveyed for the occurrence of premature ovarian failure. In 460 women, premature ovarian failure was mainly influenced by alkylating chemotherapy use with a linear dose relationship between alkylating chemotherapy and premature ovarian failure occurrence. Premature ovarian failure risk increased by 23% per year of age at treatment. In women treated without alkylating chemotherapy before age 32 years and at age 32 years or older, cumulative premature ovarian failure risks were 3% and 9%, respectively. If menstruation returned after treatment, cumulative premature ovarian failure risk was independent of age at treatment. Among women who ultimately developed premature ovarian failure, 22% had one or more children after treatment, compared with 41% of women without premature ovarian failure. This report indicates that women with proven fertility after treatment can still face infertility problems at a later stage.[47]

Fertility

Fertility was evaluated among the 6,224 male CCSS participants aged 15 to 44 years who were not surgically sterile. They were less likely to sire a pregnancy than siblings (hazard ratio [HR] 0.56; 95% CI, 0.49–0.63). Among survivors, the HR of siring a pregnancy was decreased by radiation therapy greater than 750 cGy to the testes (HR = 0.12; 95% CI, 0.02–0.64), higher summed alkylating agent dose score or treatment with cyclophosphamide (third tertile - HR = 0.42; 95% CI, 0.31–0.57) or procarbazine (second tertile - HR = 0.48; 95% CI, 0.26–0.87; third tertile – HR = 0.17; 95% CI, 0.07–0.41). The HR of siring a pregnancy was inversely related to the summed alkylating agent dose score (P -value for linear trend = <.001). Those who had a summed alkylating agent dose score of 2 (HR = 0.67; 95% CI, 0.51–0.88; P = .004), 3 (HR = 0.48; 95% CI, 0.36–0.65; P <.001), 4 (HR = 0.34; 95% CI, 0.22–0.52; P <.001), 5 (HR = 0.38; 95% CI, 0.22–0.66; P <.001), or 6 to 11 (HR = 0.16; 95% CI, 0.08–0.32; P <.001) were also less likely to ever sire a pregnancy compared with those who did not receive any alkylating agents. Compared with siblings, the HR for ever siring a pregnancy for survivors who had an alkylating agent dose score of 0 and a hypothalamic/pituitary radiation dose of 0 cGy and a testes radiation dose of 0 cGy was 0.91 (95% CI, 0.73–1.14; P = .41).[48]

1|2|3|4|5|6|7

WebMD Public Information from the National Cancer Institute

Last Updated: February 25, 2014
This information is not intended to replace the advice of a doctor. Healthwise disclaims any liability for the decisions you make based on this information.
Next Article:

Today on WebMD

Building a Support System
Blog
cancer fighting foods
SLIDESHOW
 
precancerous lesions slideshow
SLIDESHOW
quit smoking tips
SLIDESHOW
 
Jennifer Goodman Linn self-portrait
Blog
what is your cancer risk
HEALTH CHECK
 
colorectal cancer treatment advances
Video
breast cancer overview slideshow
SLIDESHOW
 
prostate cancer overview
SLIDESHOW
lung cancer overview slideshow
SLIDESHOW
 
ovarian cancer overview slideshow
SLIDESHOW
Actor Michael Douglas
Article